Nigeria Receives Breakthrough HIV Prevention Injection Lenacapavir
Nigeria has officially received Lenacapavir, a long-acting HIV prevention injection, marking a significant and transformative step in the country's ongoing efforts to combat the HIV epidemic. This breakthrough medication was approved by the Coordinating Minister of Health and Social Welfare, Ali Pate, with crucial support from the Global Fund, underscoring a collaborative approach to public health innovation.
Innovative Prevention Method
Lenacapavir is specifically designed for pre-exposure prophylaxis (PrEP), offering a highly effective alternative to daily oral HIV prevention drugs. The injectable treatment is administered just twice a year, providing people at risk of HIV infection with a more convenient and manageable option compared to the routine of daily medication. This advancement is expected to address key challenges in treatment adherence.
Expert Insights and Benefits
Health experts emphasize that the new injection could significantly improve treatment adherence, particularly among individuals who find it difficult to maintain a daily drug routine. According to Adebobola Bashorun, the National Coordinator of the National HIV Viral Hepatitis and STDs Control Programme (NASCP), the arrival of Lenacapavir highlights Nigeria's strong commitment to using evidence-based innovations to accelerate progress toward controlling the epidemic.
Bashorun elaborated that expanding prevention options and strengthening service delivery will help reduce new infections and improve health outcomes across the country. He added that NASCP, working alongside partners and stakeholders, will ensure the safe rollout and effective integration of Lenacapavir into Nigeria's national HIV prevention programmes, ensuring broad accessibility and impact.
Availability and Cost
Lenacapavir is expected to become available in Nigeria and 119 other low- and middle-income countries at an estimated annual cost of about $40 per person. This affordability follows voluntary licensing agreements with generic pharmaceutical manufacturers, making the treatment more accessible to those in need. Health officials assert that the introduction of this long-acting injection moves Nigeria closer to the ambitious goal of ending HIV as a public health threat, reinforcing the nation's proactive stance in global health initiatives.
